Outcomes of a complementary and alternative medicine based on vitamins,herbal products,and amino acid as a first line treatment in idiopathic overactive bladder syndrome in men and women without bladder outlet obstruction

Abstract

Objective:

To evaluate the efficacy and tolerability of a complementary and alternative medicine (CAM) called Kubiker (Naturmed, Montegranaro, FM, Italy), consisting of vitamins (C and D), herbal products (cucurbita maxima, capsicum annum, polygonum cuspidatum), and amino acid L-Glutamine, as first line treatment of (OAB)

Materials and methods:

According to institutional protocols, data on patients addressing to a tertiary referral centre for OAB symptoms were recorded. OAB was evaluated through validated questionnaires including ICIQ-SF, USS, and OAB-q-SF. Patients with previous antimuscarinic or β3 agonist treatment, neurological disease or pathologies which may mimic OAB, including infections, were excluded. Only unobstructed patients were considered and were given CAM twice daily for 12 weeks. After treatment, symptoms were re-evaluated repeating previous questionnaires and PGI-I was given to evaluate perceived improvement.

Results:

A total of 41 patients were evaluated and 35 respected inclusion criteria and were enrolled. All subjects had a full compliance and adherence with CAM medication intake. The median patient’s age was 65 (56–73). Male were 8 (22.9%) while females were 27 (77.1%). Median baseline OAB-q SF and ICIQ-SF scores were 18 (15–25) and 9 (6–13), respectively. After treatment, 85.7% patients had a clinical benefit, with a significant reduction of OAB symptoms, also according to USS (p < 0.01). The median OAB-q SF and ICIQ-SF scores were 10 (7–15) and 6 (0–8) (p < 0.01). CAM was successful with an improvement in subjective patient’s satisfaction, with a median PGI-I score of 2 (1–3). Patients (men and women) who still had UUI after 3 months CAM medication were eight (22.8%), and among them, those who did not refer any therapeutic benefit were five (14.3%)

Conclusions:

According to our study, CAM may be useful medication for a first line treatment of uncomplicated idiopathic OAB cases, providing a nonnegligible effects on symptoms. However, further studies are mandatory to draw definitive conclusions

Keywords

OAB complementary and alternative medicine Kubiker overactive bladder urge

Get full access to this article

View all access options for this article.

References

Abrams

Cardozo

Fall

, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 2003; 61(1): 37–49.

Vaughan

Johnson

2nd Ala-Lipasti

, et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol 2011; 59(4): 629–636.

Coyne

Sexton

Thompson

, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104(3): 352–360.

Persu

Chapple

Cauni

, et al. Pelvic organ prolapse quantification system (POP-Q): a new era in pelvic prolapse staging. J Med Life 2011; 4(1): 75–81.

Haylen

Ashby

Sutherst

, et al. Maximum and average urine flow rates in normal male and female populations: the Liverpool nomograms. Br J Urol 1989; 64(1): 30–38.

Acquadro

Kopp

Coyne

, et al. Translating overactive bladder questionnaires in 14 languages. Urology 2006; 67(3): 536–540.

Coyne

Margolis

Hsieh

, et al. Validation of the urinary sensation scale (USS). Neurourol and Urodyn 2011; 30(3): 360–365.

Tubaro

Zattoni

Prezioso

, et al. Italian validation of the international consultation on incontinence questionnaires. BJU Int 2006; 97(1): 101–108.

Srikrishna

Robinson

Cardozo

. Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J 2010; 21(5): 523–528.

10.

Vaughan

Johnson

2nd Goode

, et al. Vitamin D and lower urinary tract symptoms among us men: results from 2005 to 2006 national health and nutrition examination survey. Urology 2011; 78(6): 1292–1297.

11.

Elshazly

Sultan

Aboutaleb

, et al. Vitamin D deficiency and lower urinary tract symptoms in males above 50 years of age. Urol Ann 2017; 9(2): 170–173.

12.

Gau

J-T

. Urinary incontinence resolved after adequate vitamin D supplementation: a report of two cases. J Am Geriatr Soc 2010; 58(12): 2438–2439.

13.

Maserejian

Giovannucci

McVary

, et al. Intakes of vitamins and minerals in relation to urinary incontinence, voiding, and storage symptoms in women: a cross-sectional analysis from the Boston Area Community Health survey. Eur Urol 2011; 59(6): 1039–1047.

14.

Nishimura

Ohkawara

Sato

, et al. Pumpkin seed oil extracted from Cucurbita maxima improves urinary disorder in human overactive bladder. J Tradit Complement Med 2014; 4(1): 72–74.

15.

Abdel-Rahman

. Effect of pumpkin seed (Cucurbita pepo L.) diets on benign prostatic hyperplasia (BPH): chemical and morphometric evaluation in rats. World J Chem 2006; 1: 33–40.

16.

Kirino

Takasuka

Nishi

, et al. Analysis and functionality of major polyphenolic components of Polygonum cuspidatum (Itadori). J Nutr Sci Vitaminol 2012; 58(4): 278–286.

17.

Apostolidis

Gonzales

Fowler

. Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 2006; 50(6): 1299–1305.

18.

Soda

Tashiro

Koike

, et al. Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn 2020; 39(8): 2527–2534.

19.

Vecchioli-Scaldazza

Morosetti

Maruccia

, et al. A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (cam) versus Solifenacin succinate in women with overactive bladder syndrome. Archivio Italiano di Urologia e Andrologia 2017; 89(4): 296–300.